All Articles

Gilgamesh Lands Government Grant To Solve Opioid Addiction

March 16, 2024
x min read

A psychedelic drug development company is taking on the opioid crisis. And they just landed a historic new grant to do it.

What’s happening:

  • Psychedelic biotechnology company Gilgamesh has received a $14M USD grant from the National Institute on Drug Abuse to advance the clinical development of their novel cardiac-safe ibogaine analogue for the treatment of substance abuse disorders

Why it matters:

  • Ibogaine has shown clinical validation as an effective therapeutic for dealing with drug addiction, however it has cardiovascular toxicity which has made it both dangerous and difficult to develop as a pharmaceutical
  • Gilgamesh believes they have developed a potential breakthrough with their novel molecule GM-3009 which is cardiac-safe and has shown promising therapeutic potential for patients dealing with opioid addiction

By the numbers:

  • Last year alone in the United States, over 100,000 individuals died from opioids

Going deeper:

  • Psychedelic drug developers have recently been making big strides with regulators, as both MindMed (NASDAQ: MNMD) and Cynin (NYSE: CYBN) have recently received Breakthrough Therapy designations from the FDA
  • The new grant funding from the National Institute on Drug Abuse will be non-dilutive capital and will help advance clinical trials to further validate that GM-3009 eliminates the cardiovascular risks associated with ibogaine

Discover what’s next. The world’s biggest ideas, disruptive trends, most exciting early stage companies and groundbreaking entrepreneurs.

By clicking Subscribe you're confirming that you agree with our Privacy Policy.
Thanks for subscribing!
Keep an eye out for a welcome email shortly.
Oops! Something went wrong while submitting the form.